Before the first submission-supporting study is designed, and again at the point of scale-up. Diagnostic companies most often need help when analytical and clinical performance work has been executed well scientifically but documented in a way that does not support a regulatory claim.
The gap is usually documentation, not science
Diagnostic teams are typically strong at the assay. What creates delay is study documentation that cannot be tied to a defined intended use, protocols amended mid-study without rationale, and reagent lot histories that do not support the claimed performance.
Correcting that after the fact means repeating work. Setting the documentation structure before the study is written costs a fraction of it.
Two natural entry points
- Ahead of analytical and clinical performance studies, to align protocols, acceptance criteria and the intended use statement
- At transfer from development to routine manufacturing, when specifications, controls and lot release criteria have to be fixed
Quality system timing
A growing diagnostic company does not need a fully built quality system on day one, but it does need the design and document controls in place before design outputs start accumulating. Retrofitting a design history file is one of the more expensive exercises in this sector.
References
Reviewed by the named consultant. Last updated July 14, 2026. General information only — not regulatory or legal advice for a specific situation.